Literature DB >> 24355641

Definitions and diagnosis of pulmonary hypertension.

Marius M Hoeper1, Harm Jan Bogaard2, Robin Condliffe3, Robert Frantz4, Dinesh Khanna5, Marcin Kurzyna6, David Langleben7, Alessandra Manes8, Toru Satoh9, Fernando Torres10, Martin R Wilkins11, David B Badesch12.   

Abstract

Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥ 25 mm Hg at rest, measured during right heart catheterization. There is still insufficient evidence to add an exercise criterion to this definition. The term pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg and a pulmonary vascular resistance >3 Wood units. Right heart catheterization remains essential for a diagnosis of PH or PAH. This procedure requires further standardization, including uniformity of the pressure transducer zero level at the midthoracic line, which is at the level of the left atrium. One of the most common problems in the diagnostic workup of patients with PH is the distinction between PAH and PH due to left heart failure with preserved ejection fraction (HFpEF). A normal PAWP does not rule out the presence of HFpEF. Volume or exercise challenge during right heart catheterization may be useful to unmask the presence of left heart disease, but both tools require further evaluation before their use in general practice can be recommended. Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing including diffusion capacity for carbon monoxide, biomarkers, and echocardiography has a higher predictive value than echocardiography alone.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CO; CTD; DLCO; HFpEF; HPAH; IPAH; LVEDP; N-terminal pro–B-type natriuretic peptide; NT-proBNP; PAH; PAPm; PAWP; PH; PVR; RHC; SSc; WU; Wood units; cardiac output; connective tissue disease; diagnosis; diffusion capacity for carbon monoxide; heart failure with preserved ejection fraction; hemodynamics; heritable pulmonary arterial hypertension; idiopathic pulmonary arterial hypertension; left ventricular end-diastolic pressure; mean pulmonary artery pressure; pulmonary arterial hypertension; pulmonary artery wedge pressure; pulmonary hypertension; pulmonary vascular resistance; right heart catheterization; scleroderma; screening

Mesh:

Year:  2013        PMID: 24355641     DOI: 10.1016/j.jacc.2013.10.032

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  500 in total

1.  Changes in main pulmonary artery diameter during follow-up have prognostic implications in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Scott Johnson; Laith Alkukhun; Ruchi Yadav; Raed A Dweik
Journal:  Respirology       Date:  2017-05-17       Impact factor: 6.424

Review 2.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

3.  Atrial Septal Defect as Unexpected Cause of Pulmonary Artery Hypertension.

Authors:  Rushi V Parikh; Jack Boyd; David P Lee; Ronald Witteles
Journal:  Tex Heart Inst J       Date:  2018-02-01

4.  Sex-specific cardiopulmonary exercise testing parameters as predictors in patients with idiopathic pulmonary arterial hypertension.

Authors:  Ping Yuan; Hui-Juan Ni; Tian-Xiang Chen; Bigyan Pudasaini; Rong Jiang; Hui Liu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Jin-Ming Liu
Journal:  Hypertens Res       Date:  2017-06-01       Impact factor: 3.872

5.  NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis.

Authors:  Li-Huang Zha; Jun Zhou; Tang-Zhiming Li; Hui Luo; Jing-Ni He; Lin Zhao; Zai-Xin Yu
Journal:  Aging Dis       Date:  2018-10-01       Impact factor: 6.745

6.  Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Authors:  John H Newman; Stuart Rich; Steven H Abman; John H Alexander; John Barnard; Gerald J Beck; Raymond L Benza; Todd M Bull; Stephen Y Chan; Hyung J Chun; Declan Doogan; Jocelyn Dupuis; Serpil C Erzurum; Robert P Frantz; Mark Geraci; Hunter Gillies; Mark Gladwin; Michael P Gray; Anna R Hemnes; Roy S Herbst; Adrian F Hernandez; Nicholas S Hill; Evelyn M Horn; Kendall Hunter; Zhi-Cheng Jing; Roger Johns; Sanjay Kaul; Steven M Kawut; Tim Lahm; Jane A Leopold; Greg D Lewis; Stephen C Mathai; Vallerie V McLaughlin; Evangelos D Michelakis; Steven D Nathan; William Nichols; Grier Page; Marlene Rabinovitch; Jonathan Rich; Franz Rischard; Sharon Rounds; Sanjiv J Shah; Victor F Tapson; Naomi Lowy; Norman Stockbridge; Gail Weinmann; Lei Xiao
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

7.  Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

Authors:  Chiara Federici; Kylie M Drake; Christina M Rigelsky; Lauren N McNelly; Sirena L Meade; Suzy A A Comhair; Serpil C Erzurum; Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

8.  Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rebecca R Vanderpool; Melissa Saul; Mehdi Nouraie; Mark T Gladwin; Marc A Simon
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Clinical characteristics of pulmonary hypertension in bronchiectasis.

Authors:  Lan Wang; Sen Jiang; Jingyun Shi; Sugang Gong; Qinhua Zhao; Rong Jiang; Ping Yuan; Bigyan Pudasaini; Jing He; Zhicheng Jing; Jinming Liu
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.